Previous 10 | Next 10 |
Assembly Biosciences (ASMB) has announced to wind-down its microbiome program, enabling the company to prioritize resources and focus on hepatitis B virus programs.While Assembly Bio will continue its ongoing review of potential strategic options for the microbiome program in the interim...
SOUTH SAN FRANCISCO, Calif., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced that it will wind-down its microbiome program, enabling the ...
SOUTH SAN FRANCISCO, Calif., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced the appointment ...
Assembly Biosciences (ASMB) and Door Pharmaceuticals have signed an exclusive, two-year collaboration and option agreement focused on the development of a class of hepatitis B virus ((HBV)) core protein modulators.Under the terms of the agreement, Door Pharmaceuticals will build upon its prev...
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB) and Door Pharmaceuticals, LLC today announced that the companies have signed an exclusive, two-year collaboration and option agreement focused on the development of a novel class of...
- Data show longer-term, differentiated safety profile of vebicorvir and the importance of HBV preg e n o mic ( pg ) RNA as a key biomarker , as well as highlight Assembly Bio’s core inhibitor clinical pipeline...
Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks faded late to finish mostly flat on Friday, as investors awaited final election vote tallies in four key states, and stimulus negotiat...
Shares of Assembly Biosciences (NASDAQ: ASMB) crashed on Friday, plunging 69.4% as of the market close. The huge drop came after the company announced disappointing results Thursday evening from a phase 2 study evaluating vebicorvir (VBR) in treating patients with chronic hepatitis ...
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced a grant of stock...
Gainers: Aurora Cannabis (ACB) +75%.Sundial Growers (SNDL) +57%.Modine Manufacturing (MOD) +41%.Akerna (KERN) +40%.Tilray (TLRY) +40%.Cooper-Standard (CPS) +35%.Mogo (MOGO) +32%.OrganiGram (OGI) +29%.Glu Mobile (GLUU) +28%.FTS International (FTSI) +21%.Losers: Assembly Bioscien...
News, Short Squeeze, Breakout and More Instantly...
Assembly Biosciences Inc. Company Name:
ASMB Stock Symbol:
NASDAQ Market:
Assembly Biosciences Inc. Website:
2024-07-16 14:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
– Data from both ABI-5366 and ABI-1179, novel long-acting helicase-primase inhibitor candidates for recurrent genital herpes, to be presented – – Poster presentation highlights key preclinical data from ABI-5366 supporting its entry into ongoing Phase 1a/b clinical ...
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the first participant has been dosed in the Phase 1b trial of ABI-4334, a nex...